TrialPath
Type 2 diabetes · Chicago

Type 2 diabetes clinical trials in Chicago

20 recruiting type 2 diabetes studies within range of Chicago. Click any trial for full eligibility criteria and contact info.

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549 · Obesity, Overweight and/or Obesity, Overweight
Recruiting

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.

PhasePhase 3
TypeInterventional
Age18 Years
WhereCanoga Park, California, United States + 79 more
SponsorPfizer
▾Tap for details
Apply

Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System

Recruiting

This multi-center, randomized, cross-over trial will evaluate the efficacy of the Omnipod 6 System compared with the Omnipod 5 System in individuals with type 1 or type 2 diabetes and suboptimal glycemia.

PhaseNA
TypeInterventional
Age14 Years – 75 Years
WhereLos Angeles, California, United States + 10 more
SponsorInsulet Corporation
▾Tap for details
Apply

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

NCT07589608 · Overweight, Obesity
Recruiting

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereChandler, Arizona, United States + 39 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus

NCT07527650 · Type 2 Diabetes Mellitus, T2DM
Recruiting

This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereMesa, Arizona, United States + 19 more
SponsorHanmi Pharmaceutical Company Limited
▾Tap for details
Apply

Evaluation of the Fully Closed Loop Omnipod® System in Type 2 Diabetes

Recruiting

A multi-center, 26-week randomized controlled trial (RCT) to evaluate the safety and efficacy of the fully closed loop Omnipod M System in adults with type 2 diabetes using basal/bolus insulin therapy or basal-only insulin therapy, with the primary endpoint after 15 weeks and secondary analysis at 26 weeks; followed by an extension phase after completion of the 26-week trial where the Intervention group will continue to use Omnipod M and the Control group will crossover to use Omnipod M for 26 weeks

PhaseNA
TypeInterventional
Age18 Years – 75 Years
WhereLos Angeles, California, United States + 26 more
SponsorInsulet Corporation
▾Tap for details
Apply

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

NCT06112418 · Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome
Recruiting

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

PhaseNA
TypeInterventional
Age55 Years
WhereChandler, Arizona, United States + 124 more
SponsorCleerly, Inc.
▾Tap for details
Apply

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954 · Diabetes Mellitus, Type 2
Recruiting

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereLancaster, California, United States + 62 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484 · Type 2 Diabetes, Cortisol Excess
Recruiting

CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in the double-blind (participant and investigator), dose-ranging, interventional Part 2 (Treatment).

PhasePhase 2
TypeInterventional
Age18 Years
WhereChandler, Arizona, United States + 60 more
SponsorSparrow Pharmaceuticals
▾Tap for details

A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 Diabetes

NCT04786262 · Diabetes Mellitus, Type 1, Impaired Hypoglycemic Awareness, Severe Hypoglycemia
Recruiting

This study will evaluate the safety, tolerability and efficacy of VX-880 infusion and VX-017 infusion in participants with type 1 diabetes (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereDuarte, California, United States + 28 more
SponsorVertex Pharmaceuticals Incorporated
▾Tap for details
Apply

My ESSENCE - A Research Study on Mindfulness for African-Americans With Type 2 Diabetes

NCT05208164 · Type 2 Diabetes, Sleep, Stress
Recruiting

The proposed research and training will allow Dr. Alana Biggers to obtain critical research skills and study a mindfulness meditation program designed to improve sleep and reduce stress in African-American adults with diabetes. If effective, this program may reduce the risk of cardiovascular disease among African-Americans with type 2 diabetes who are at high risk of cardiovascular disease.

PhaseNA
TypeInterventional
Age21 Years – 75 Years
WhereChicago, Illinois, United States
SponsorUniversity of Illinois Chicago
▾Tap for details
Apply

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

NCT05390892 · Type2Diabetes, ASCVD
Recruiting

PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-2 inhibitor (SGLT2i) or glucagon-like peptide-1 receptor agonists (GLP-1RA). Participants will be followed for the occurrence of the trial primary endpoint of the total (first and recurrent) number of episodes of myocardial infarction (MI), stroke, arterial revascularization, hospitalization for heart failure, development of end-stage kidney disease, kidney transplantation, and mortality, counting all events from randomization until end of study.

PhasePhase 4
TypeInterventional
Age40 Years – 80 Years
WhereHuntsville, Alabama, United States + 35 more
SponsorBrigham and Women's Hospital
▾Tap for details
Apply

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort

NCT07024823 · Chronic Kidney Disease
Recruiting

This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).

PhasePhase 1
TypeInterventional
Age18 Years – 75 Years
WhereGlendale, California, United States + 4 more
SponsorAstraZeneca
▾Tap for details
Apply

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

NCT07784725 · Obesity or Overweight
Recruiting

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

PhasePhase 3
TypeInterventional
Age18 Years
WhereDothan, Alabama, United States + 219 more
SponsorAstraZeneca
▾Tap for details
Apply

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

NCT06739122 · Type 2 Diabetes
Recruiting

The main purpose of this study is to evaluate additional dosing options for dulaglutide in pediatric participants with Type 2 Diabetes. Participation in this study will last about 8 months.

PhasePhase 3
TypeInterventional
Age10 Years – 17 Years
WhereTucson, Arizona, United States + 50 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Achieving Routine Intervention and Screening for Emotional Health

NCT06887049 · Type 2 Diabetes Mellitus (T2DM), Diabetes Distress
Recruiting

The purpose of this project is to evaluate the effectiveness of diabetes distress screening and intervention on patients with type 2 diabetes mellitus (T2DM).

PhaseNA
TypeInterventional
Age18 Years
WhereChicago, Illinois, United States
SponsorUniversity of Chicago
▾Tap for details
Apply

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

NCT07064473 · Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Recruiting

This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin. Participants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine. Participants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo. Participants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.

PhasePhase 3
TypeInterventional
Age18 Years
WhereAnniston, Alabama, United States + 1141 more
SponsorBoehringer Ingelheim
▾Tap for details
Apply

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

NCT07271186 · Diabetic Kidney Disease (DKD)
Recruiting

This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereHuntsville, Alabama, United States + 58 more
SponsorRegeneron Pharmaceuticals
▾Tap for details
Apply

A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus

Recruiting

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

PhasePhase 3
TypeInterventional
Age18 Years
WhereHuntsville, Alabama, United States + 302 more
SponsorAstraZeneca
▾Tap for details
Apply

AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

NCT07797335 · Type 2 Diabetes, Cardiovascular Risk
Recruiting

This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get zenagamtide, (the treatment being tested) or insulin glargine (a comparator) and which treatment participants get is decided by chance.

PhasePhase 3
TypeInterventional
Age45 Years
WhereBirmingham, Alabama, United States + 329 more
SponsorNovo Nordisk A/S
▾Tap for details
Apply

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

Recruiting

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron, compared with placebo in adults with type 2 diabetes mellitus (T2DM) and impaired renal function, who are or will be on a background of sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin 10 mg as per guideline directed medical therapy (GDMT) for chronic kidney disease (CKD). Additionally, participants are on other glucose-lowering medication(s).

PhasePhase 3
TypeInterventional
Age18 Years
WhereSun City, Arizona, United States + 185 more
SponsorAstraZeneca
▾Tap for details
Apply